"An MDL that encompassed any potential injury relating to use of these exceedingly popular weight loss drugs might quickly ...
Novo Nordisk stock fell sharply early Friday after the pharmaceutical giant, known for its blockbuster drugs Ozempic and ...
Eli Lilly just gave investors several reasons to cheer.
The federal government is phasing out off-brand copies of two blockbuster drugs used to treat obesity and diabetes ...
Nestle just rolled out a new protein shot drink that it says will help people looking to lose weight manage their hunger and ...
As of 11:05 a.m. ET, Novo Nordisk stock is down a disheartening 20.8%, while both Lilly and Viking stocks are up 4.4% apiece.
The updates from clinical trials of Eli Lilly's competitors in the obesity market were largely underwhelming this year. See ...
9d
Eli Lilly, the pharma giant behind the popular weight-loss drug Zepbound, said it plans to test obesity medications as a ...
The FDA has doubled down on its decision to remove Eli Lilly’s tirzepatide from its list of products that are in shortage. | ...
Lilly investors got the jitters, saw better opportunities elsewhere, or decided to hold onto their chips. In the third ...
With U.S. headquarters in Plainsboro, Novo Nordisk told NJBIZ, "NAION is a very rare eye disease, and it is not an adverse ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback